Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Does UnitedHealthcare Cover Vyvanse? Formulary Tier, Prior Authorization, and Appeal Steps

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Coverage terms / set by your plan's formulary and coverage criteria, not by the FDA label
  • Approved uses / ADHD in adults and children 6 and older; moderate to severe binge eating disorder in adults [1]
  • Not an approved use / weight loss; the label states Vyvanse is not indicated for weight loss [1]
  • Controlled substance / Schedule II, prescription only [1]
  • Brand forms / capsules 10 to 70 mg (NDA 021977) and chewable tablets 10 to 60 mg (NDA 208510), Takeda [2][3]
  • Oral solution / Arynta (lisdexamfetamine) 10 mg/mL, Azurity, approved 16 June 2025 [4]
  • Generics / lisdexamfetamine capsules and chewable tablets, first FDA-approved 23 August 2023 [2][4]

What the label establishes

Vyvanse is the brand name for lisdexamfetamine dimesylate, an inactive prodrug converted in the body to dextroamphetamine [1]. Two brand forms are approved: capsules of 10, 20, 30, 40, 50, 60 and 70 mg under NDA 021977, and chewable tablets of 10 to 60 mg under NDA 208510, both from Takeda [2][3]. Vyvanse is prescription-only and Schedule II, and its only boxed warning covers abuse, misuse and addiction [1].

The approved indications are ADHD in adults and children 6 years and older, and moderate to severe binge eating disorder in adults [1]. The label states that Vyvanse is not indicated for weight loss and that its safety and effectiveness for obesity have not been established [1].

Where the coverage answer lives

The FDA label does not state a UnitedHealthcare tier, prior authorization rule, step requirement or appeal deadline [1]. Those details sit in the formulary and coverage documents for your exact plan and plan year, so a tier or requirement read from one UnitedHealthcare document may not describe another.

Which product the plan lists

Generic lisdexamfetamine capsules and chewable tablets have been FDA-approved since 23 August 2023, and a lisdexamfetamine oral solution, Arynta 10 mg/mL from Azurity, was approved on 16 June 2025 [2][4]. Vyvanse itself comes as capsules and as chewable tablets under separate applications [2][3]. A formulary line for lisdexamfetamine can therefore point at more than one product and form, and the tier and criteria attached to each can differ. Match the formulary entry to the exact product, form and strength.

If coverage is denied

The denial notice states the reason and the criterion the plan applied, and it is the place to look for the appeal instructions, the filing deadline and any external-review option.

Frequently asked questions

Does UnitedHealthcare cover Vyvanse?
That depends on your specific plan. Vyvanse is approved for ADHD in adults and children 6 and older and for moderate to severe binge eating disorder in adults [1], but the label does not state what any plan covers. The plan's formulary lists whether Vyvanse and generic lisdexamfetamine are covered.
What tier is Vyvanse on at UnitedHealthcare?
Tier is set per plan and can differ by product and form: brand capsule, brand chewable tablet, generic lisdexamfetamine, or an oral solution such as Arynta [2][3][4]. The plan's formulary entry for the exact product shows the tier.
Does UnitedHealthcare require prior authorization or step therapy for Vyvanse?
The FDA label does not state any prior authorization or step requirement [1]. Those requirements are written in the plan's coverage criteria for lisdexamfetamine.
Is Vyvanse covered for weight loss?
Vyvanse is not indicated for weight loss, and the label states its safety and effectiveness for obesity have not been established [1]. The approved uses are ADHD in adults and children 6 and older, and moderate to severe binge eating disorder in adults [1].
How do I appeal a denial?
The denial notice and your benefit documents give the appeal instructions, the filing deadline and any external-review option for your plan. The reason in the notice identifies the criterion the appeal has to answer.

References

  1. U.S. National Library of Medicine, DailyMed. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, Takeda prescribing information. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, Takeda label
  2. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  3. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  4. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
Evidence overview for Does UnitedHealthcare Cover Vyvanse? Formulary Tier, Prior Authorization, and Appeal Steps